Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals5.11%-0.44 ppLife Sciences Tools & Services1.52%-0.39 ppManaged Health Care2.39%-0.34 ppBiotechnology2.47%-0.26 ppHealth Care Services0.74%-0.19 ppHealth Care Equipment2.79%-0.11 ppHealth Care Distributors0.44%+0.02 ppHealth Care Facilities0.21%-0.02 ppHealth Care Supplies0.14%+0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.47%
Industry change · 12M
-0.26 pp
Biotechnology · contribution
-0.259 pp
Company participation
88%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Oct 2023 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $28.9bn | 0.098% | +0.001 pp | -0.110 pp | -49.5% | No |
| AbbVie → ABBV | United States | $249.2bn | 0.847% | +0.272 pp | -0.071 pp | +0.3% | Yes |
| Amgen → AMGN | United States | $136.8bn | 0.465% | +0.193 pp | -0.048 pp | -2.2% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $93.5bn | 0.318% | +0.120 pp | +0.034 pp | +16.1% | Yes |
| Biogen → BIIB | United States | $34.4bn | 0.117% | +0.032 pp | -0.028 pp | -16.2% | Yes |
| Incyte → INCY | United States | $12.1bn | 0.041% | +0.010 pp | -0.018 pp | -27.5% | Yes |
| Gilead Sciences → GILD | United States | $97.9bn | 0.333% | +0.126 pp | -0.016 pp | +3.9% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $73.3bn | 0.249% | +0.097 pp | -0.001 pp | +4.2% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.